Journal Of Experimental Medicine

Journal of Experimental Medicine (journal-of-experimental-medicine)

Journal positioning

The Journal of Experimental Medicine, published by Rockefeller University Press, is one of the oldest and most selective journals in immunology and experimental medicine. It publishes mechanistic studies of immune system function, host-pathogen interaction, hematopoiesis, and the immunobiology of disease — judged on the depth of mechanistic dissection and the degree to which findings illuminate a generalizable biological principle, not just a clinical phenotype. The readership is bench-level immunologists, hematologists, and disease biologists who expect rigorous in vivo experimental evidence. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Rockefeller University Press / JEM site.

When to trigger

• The author names JEM or Journal of Experimental Medicine as the target venue.
• A mechanistic immunology or disease-biology study has in vivo depth and seeks a prestigious society-press venue below the Nature/Cell Press flagship tier.
• A manuscript involves hematopoiesis, lymphocyte biology, innate sensing, autoimmunity, or infection mechanisms and needs venue-calibration.
• The author needs JEM's desk-reject risks and a credible alternative routing in immunology or experimental medicine.

Scope & topic fit

• Mechanistic immunology: lymphocyte development, activation, tolerance, and memory; myeloid cell biology and function in disease.
• Hematopoiesis and bone-marrow niche biology; hematologic malignancies with mechanistic grounding.
• Host-pathogen interaction with immunological depth: innate sensing, cytokine networks, immune evasion mechanisms.
• Autoimmunity, inflammatory disease, and allergy — mechanism-forward, not purely descriptive clinical characterization.
• Tumor immunology with clear mechanistic dissection of immune-tumor crosstalk.
• Translational extension is valued when mechanistic findings in model systems are connected to human disease biology through patient samples or human genetic evidence.

Method & evidence bar

• In vivo mouse models or equivalent are expected as the mechanistic platform; human data are highly valued as orthogonal validation.
• Genetic dissection — conditional knockouts, lineage tracing, adoptive transfer, bone-marrow chimera — is the expected toolkit, not just pharmacological perturbations.
• Mechanistic claims require multi-level validation: phenotype + molecular pathway + rescue or gain-of-function confirmation.
• Human patient samples (primary cells, patient-derived material, genetic variants) strengthen translational relevance and are frequently required for papers framed as disease-mechanism studies.
• Quantitative imaging, flow cytometry, single-cell genomics, and structural biology are appropriate but must serve the mechanistic argument rather than being presented as endpoints.

Structure & house style

• Standard IMRAD structure with unstructured abstract; JEM does not use STAR Methods — Methods are in the main manuscript or supplemental material.
• The introduction must foreground the biological question and unanswered mechanistic gap; "we show X" is not a sufficient opening rationale; the gap in current understanding must be stated precisely.
• Supplemental figures and materials carry additional experimental validation; the main figures should tell a complete mechanistic story without requiring recourse to supplemental for the central argument.
• Rockefeller University Press uses a transparent peer-review option: review reports and author responses can be posted publicly alongside the published paper; authors can opt in at submission — factor this into how revision letters are written.
• Brief Definitive Reports for shorter, focused mechanistic findings; Research Articles for full mechanistic stories — check current article types and associated figure/length constraints on the live site.
• JEM's editorial culture values classical, deep experimental rigor over large-scale omics surveys; the benchmark is whether the biological principle is proven, not just observed.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the official source anchors for this journal family, then cite the current journal-specific page you checked.
• Search the live site for "Journal of Experimental Medicine author information" and follow the current Rockefeller University Press version.
• Re-check article-type definitions (Research Articles, Brief Definitive Reports, Correspondence) and their current length/figure norms.
• Confirm data and materials availability: genomics data deposition (GEO, SRA), reagent sharing expectations, and any current open-data policy requirements.
• Verify animal experiment compliance: IACUC/ethics approval, ARRIVE reporting standards; human samples: IRB, informed consent.
• Check competing-interests, funding disclosure, and current preprint/posting policy.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• One sentence stating the mechanistic principle illuminated, generalizable beyond the specific cell type or pathogen studied.
• The paper includes in vivo data and genetic evidence of causality; pharmacological-only perturbation alone is insufficient for the top tier.
• Human validation or patient-sample evidence is included if the paper claims disease relevance.
• The contribution is framed against recent JEM, Immunity, or Journal of Immunology papers to establish the genuine mechanistic gap.
• Methods detail is sufficient for an expert immunologist to independently reproduce key experiments without requesting protocols.

Common desk-reject triggers

• Immunological phenotyping without mechanistic dissection of pathway, effector molecule, or signaling node.
• Studies relying exclusively on pharmacological tools (antibody depletion, inhibitors) without genetic validation.
• Clinical descriptive studies that characterize immune phenotypes in patients without mechanistic experiments.
• Scope limited to a single in vitro assay system with no in vivo validation and no compelling biological rationale for the limitation.
• Manuscripts where the human/translational connection is asserted rather than demonstrated with primary human data.

Re-routing decision

• Higher conceptual novelty and broader immunological significance → immunity (Cell Press) or nature-immunology.
• Host-microbe mechanism is primary → cell-host-and-microbe.
• Solid immunology but more incremental scope → elife, plos-biology, or the Journal of Immunology.
• Translational/clinical framing is primary → nature-medicine or science-translational-medicine.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Journal of Experimental Medicine
[Topic tags] <2–3 closest topics>
[Method/evidence] <does the in vivo mechanistic depth clear JEM's standard?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / data deposition / animal ethics / human IRB / transparent review option>
[Re-route suggestion] <if not a fit, a better-matched venue>